Cargando…
Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner
Biosimilar agents are biologic products that have been shown to be "highly similar" to an already approved reference biologic product. Their integration into clinical practice has the potential to significantly decrease costs for patients, health-care systems, and insurance companies. Thro...
Autor principal: | Campen, Christopher J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188098/ https://www.ncbi.nlm.nih.gov/pubmed/30333932 |
Ejemplares similares
-
Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice
por: Mayden, Kelley D., et al.
Publicado: (2022) -
Biosimilars in the United States: Considerations for Oncology Advanced Practitioners
por: Mayden, Kelley D., et al.
Publicado: (2015) -
The Launch of the Advanced Practitioner Society for Hematology and Oncology (APSHO)
por: Viale, Pamela Hallquist, et al.
Publicado: (2014) -
Current and future roles of biosimilars in oncology practice
por: Konstantinidou, Sofia, et al.
Publicado: (2020) -
Potential of Biosimilars to Increase Access to Biologics: Considerations for Advanced Practice Providers in Oncology
por: Tinsley, Sara M., et al.
Publicado: (2018)